Περίληψη:
The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints. © 2021 American Society for Microbiology.
Συγγραφείς:
Gill, C.M.
Aktaş, E.
Alfouzan, W.
Bourassa, L.
Brink, A.
Burnham, C.-A.D.
Canton, R.
Carmeli, Y.
Falcone, M.
Kiffer, C.
Marchese, A.
Martinez, O.
Pournaras, S.
Seifert, H.
Thabit, A.K.
Villegas, M.V.
Westblade, L.F.
Nicolau, D.P.
Wille, J.
Rezende, T.T.F.
Cekin, Z.
Malkocoglu, G.
Gijón, D.
Tarakmeh, L.A.
Chu, C.Y.
Opperman, C.J.
Tootla, H.D.
Moodley, C.
Coetzee, J.
Vourli, S.
Dimopoulos, G.
Attallah, D.M.
Tiseo, G.
Leonildi, A.
Giordano, C.
Barnini, S.
Menichetti, F.
Di Pilato, V.
Codda, G.
Vena, A.
Giacobbe, D.R.
Satlin, M.
Cardona, A.
Curtis, L.
Fang, F.
Thomson, G.
Thomson, K.
the ERACE-PA Global Study Group
Λέξεις-κλειδιά:
cefepime; ceftazidime; antiinfective agent; azabicyclo derivative; carbapenem derivative; ceftazidime; cephalosporin derivative, antibiotic sensitivity; Article; bacterium isolate; carbapenem resistant Pseudomonas aeruginosa; clinical laboratory standard; controlled study; dose calculation; drug potency; in vitro study; maximum permissible dose; MIC50; MIC90; Monte Carlo method; nonhuman; process optimization; human; microbial sensitivity test; Pseudomonas aeruginosa; Pseudomonas infection, Anti-Bacterial Agents; Azabicyclo Compounds; Carbapenems; Ceftazidime; Cephalosporins; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections
